Interfering with cell-survival signalling as a treatment strategy for prostate cancer. (Q36474196)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Interfering with cell-survival signalling as a treatment strategy for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Niall M Corcoran

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

Anthony J Costello

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

1149-1153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Coxibs and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

NF-κB nuclear localization and its prognostic significance in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1464-410X.2006.06198.X

10.1111/J.1464-410X.2006.06198.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16686702 AND SRC:MED&resulttype=core&format=json

21 January 2020

1 reference